Flumethasone

Flumethasone (Flumetasone) is an orally active, high selective and potent glucocorticoid receptor (GR) agonist. Flumethasone activates GR to inhibit nuclear factor kappa B (NF-κB) -mediated pro-inflammatory cytokine production (TNF-α, IL-1β) and promotes anti-inflammatory gene expression (IL-10), while also regulating metabolic enzyme activity (tyrosine aminotransferase induction) . Flumethasone is promising for research of inflammatory diseases, cancer, and endocrine regulation[1][2][3][4].

Product Specifications

CAS Number

[2135-17-3]

Product Name Alternative

Flumetasone

UNSPSC

12352211

Hazard Statement

H351

Target

Glucocorticoid Receptor; Interleukin Related; Keap1-Nrf2; TNF Receptor

Type

Reference compound

Related Pathways

Apoptosis; Immunology/Inflammation; NF-κB; Vitamin D Related/Nuclear Receptor

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Endocrinology; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Flumethasone.html

Purity

99.84

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

C[C@@]12[C@](C(CO)=O)(O)[C@H](C)C[C@@]1([H])[C@]3([H])C[C@H](F)C4=CC(C=C[C@]4(C)[C@@]3(F)[C@@H](O)C2)=O

Molecular Formula

C22H28F2O5

Molecular Weight

410.45

Precautions

H351

References & Citations

[1]Zhou Y, et al. Flumethasone enhances the efficacy of chemotherapeutic drugs in lung cancer by inhibiting Nrf2 signaling pathway. Cancer Lett. 2020 Apr 1;474:94-105.|[2]Blake RL. Flumethasone induction of liver tyrosine aminotransferase activity in inbred strains and obese mutant mice. Biochem Pharmacol. 1970 May;19 (5) :1803-15.|[3]Bednarek D, et al. The effect of steroidal and non-steroidal anti-inflammatory drugs on the cellular immunity of calves with experimentally-induced local lung inflammation. Vet Immunol Immunopathol. 1999 Oct 1;71 (1) :1-15.|[4]Willi RA, et al. Environmental glucocorticoids corticosterone, betamethasone and flumethasone induce more potent physiological than transcriptional effects in zebrafish embryos. Sci Total Environ. 2019 Jul 1;672:183-191.